Benzinga's Top Upgrades

Morgan Stanley upgraded Vertex Pharmaceuticals Incorporated VRTX from Equal-weight to Overweight. The price target for Vertex Pharmaceuticals has been raised from $118 to $148. Vertex Pharmaceuticals shares closed at $107.23 on Thursday. Credit Suisse upgraded Ollie's Bargain Outlet Holdings Inc OLLI from Neutral to Outperform. The price target for Ollie's Bargain Outlet is set to $20. Ollie's Bargain Outlet shares closed at $16.08 on Thursday. Analysts at Goldman Sachs upgraded Finish Line Inc FINL from Sell to Neutral. The price target for Finish Line is set to $20. Finish Line shares closed at $18.92 on Thursday. Analysts at Morgan Stanley upgraded Pfizer Inc. PFE from Equal-weight to Overweight. The price target for Pfizer has been raised from $35 to $38. Pfizer shares closed at $31.84 on Thursday. UBS upgraded BlackRock, Inc. BLK from Neutral to Buy. The price target for BlackRock has been lowered from $370 to $350. BlackRock shares closed at $295.92 on Thursday. Analysts at Longbow Research upgraded Martin Marietta Materials, Inc. MLM from undefined to Buy. Martin Marietta Materials shares closed at $156.72 on Thursday. Analysts at Oppenheimer upgraded Google Inc GOOG from Perform to Outperform. The price target for Google has been raised from $670 to $700. Google shares closed at $611.29 on Thursday. UBS upgraded Northern Trust Corporation NTRS from Sell to Neutral. Northern Trust shares closed at $68.21 on Thursday. Morgan Stanley upgraded Alexion Pharmaceuticals, Inc. ALXN from Equal-weight to Overweight. The price target for Alexion Pharmaceuticals has been raised from $186 to $211. Alexion Pharmaceuticals shares closed at $157.82 on Thursday. Goldman Sachs upgraded Summit Materials Inc SUM from Neutral to Buy. The price target for Summit Materials is set to $29. Summit Materials shares closed at $19.68 on Thursday.